Marksans Pharma Limited Stock Price Today (NSE: MARKSANS)

Marksans Pharma Limited

316.45+3.60 (+1.15%)
Market Closed

Fundamental Score

...

Marksans Pharma Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Marksans Pharma Limited share price today is 316.45, up +1.15% on NSE/BSE as of 16 September 2026. Marksans Pharma Limited (MARKSANS) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of 14.34K (Cr). The 52-week high for MARKSANS share price is 349.95 and the 52-week low is 155.00. At a P/E ratio of 27.73x, MARKSANS is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 25.56% and a debt-to-equity ratio of 0.01.

Marksans Pharma Limited Share Price Chart — NSE/BSE Historical Performance

No data
High
349.95
Low
268.30
Volume
59.6L
Change
+21.62%

Marksans Pharma Limited share price chart: 21.62% return over the past month. 52-week high ₹349.95, 52-week low ₹155.00.

Marksans Pharma Limited — Last 10 Trading Days

DateOpenHighLowCloseVolume
311.80323.60307.05316.4522.64L (Cr)
330.00331.40301.10312.8522.98L (Cr)
325.00333.75324.20329.4016.32L (Cr)
329.00334.55323.80330.4012.95L (Cr)
336.00340.00328.65330.1517.84L (Cr)
337.50349.95331.60335.9050.90L (Cr)
327.50339.00326.75335.0527.98L (Cr)
333.00335.45323.45326.7516.54L (Cr)
334.30341.00331.00332.2027.26L (Cr)
321.20337.65318.75332.5065.73L (Cr)

Marksans Pharma Limited — Last 12 Months Price History

MonthOpenHighLowCloseChange
322.90349.95301.10316.45-2.00%
259.00345.50258.85321.60+24.17%
274.40281.60242.40258.35-5.85%
249.00277.00228.20272.81+9.56%
184.63264.40184.63246.19+33.34%
165.00195.68160.60184.63+11.90%
165.00178.00155.00156.89-4.92%
168.51191.74161.70173.93+3.22%
181.80187.26156.00163.85-9.87%
188.10197.80175.64180.29-4.15%
180.51201.30179.80187.95+4.12%
166.00186.72162.00182.08+9.69%

Returns & Performance

Excellent

Return on Equity (ROE)

25.56%

Profit generated per ₹1 of shareholder equity

Excellent

Return on Capital (ROCE)

32.39%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

21.08%

Average operating profit margin over 5 years

Dividend Yield

0.29%

Annual dividend as % of current share price

Marksans Pharma Limited Valuation Check

Good

Price to Earnings (P/E)

27.73x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Mid-cap
Balance of growth potential and stability.

Shareholding Pattern

Excellent

Promoter Holding

43.87%

% shares held by company founders/management

Good

FII Holding

16.76%

% shares held by foreign institutional investors

Average

DII Holding

6.57%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

169.50%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

35.61%

Revenue growth vs same quarter last year

Excellent

Revenue Growth (5-Year CAGR)

16.48%

Compounded annual revenue growth over 5 years

Poor

EPS Growth (5-Year CAGR)

9.87%

Earnings per share growth over 5 years

Good

Net Profit Growth (5-Year CAGR)

11.87%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.01x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

24.24x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

619.62 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Marksans Pharma Limited Fundamental Analysis & Valuation Benchmarking

Educational evaluation of MARKSANS across key market metrics for learning purposes.

Positive Indicators

12 factors identified

Strong Return on Equity (25.56%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (32.39%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Strong Operating Margins (21.08%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Attractive Valuation (P/E: 27.73 vs Industry: 34.89)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Robust Profit Growth (169.50%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Revenue Growth (35.61%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Consistent Growth Track Record (16.48% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.

Conservative Debt Levels (D/E: 0.01)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (24.24x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Healthy Liquidity Position (Current Ratio: 4.62)

Observation: Strong short-term liquidity to meet obligations.

Analysis: Current ratio >1.5 indicates good working capital management.

Strong Cash Generation (₹619.62 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

1 factors identified

High Price-to-Book Ratio (5.81x)

Observation: Trading at significant premium to book value.

Analysis: High P/B ratios may indicate overvaluation relative to asset base.

Marksans Pharma Limited vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Marksans Pharma Limited with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
68.7/100
316
₹14340.25
27.7
Average
25.56%
Excellent
32.39%
Excellent
0.0
Excellent
11.87%
Good
16.48%
Excellent
0.29%
66.4/100
1865
₹447445.46
37.0
Average
14.74%
Average
19.31%
Good
0.0
Excellent
31.64%
Excellent
11.78%
Good
0.82%
56.3/100
9488
₹251432.00
86.1
Average
16.19%
Good
20.38%
Excellent
0.0
Excellent
5.29%
Good
8.67%
Good
0.41%
51.4/100
4930
₹166860.78
78.8
Average
27.07%
Excellent
14.09%
Average
1.8
Average
11.56%
Good
11.80%
Good
0.76%
74.1/100
1127
₹112514.52
25.1
Average
19.74%
Good
21.77%
Excellent
0.4
Excellent
18.76%
Excellent
12.45%
Good
0.09%
40.2/100
1363
₹110118.03
32.7
Average
11.82%
Average
15.67%
Good
0.0
Excellent
10.03%
Good
8.01%
Good
0.90%
34.1/100
1937
₹104646.43
95.6
Average
18.19%
Good
21.35%
Excellent
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%
24.6/100
1699
₹97754.71
26.5
Average
9.94%
Poor
14.54%
Average
0.2
Excellent
-8.07%
Poor
6.32%
Good
0.26%
83.4/100
2100
₹96022.50
17.4
Average
26.90%
Excellent
31.80%
Excellent
0.3
Excellent
34.39%
Excellent
13.02%
Good
0.72%
41/100
1145
₹95607.50
29.6
Average
11.75%
Average
14.80%
Average
0.2
Excellent
16.54%
Excellent
12.09%
Good
0.65%
61.5/100
2265
₹93544.50
45.8
Average
12.49%
Average
13.56%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%

Marksans Pharma Limited PE Ratio History

Historical price-to-earnings ratio for MARKSANS — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 20258.40₹180.2921.5x
FY 20246.92₹296.6542.9x
FY 20236.41₹161.1025.1x
FY 20224.51₹58.2512.9x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Marksans Pharma Limited Dividend History

Annual cash dividends paid by MARKSANS — dividend yield 0.29%

Financial YearDividends Paid (₹ Cr)
FY 202527.19 Cr
FY 202422.66 Cr
FY 202310.17 Cr
FY 202210.58 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Marksans Pharma Limited Quarterly Performance

Latest quarterly metrics for MARKSANS — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

35.61%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

169.50%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

16.48%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

11.87%

Compounded annual net profit growth over 5 years

Marksans Pharma Limited Technical Indicators

SMA 50, SMA 200, RSI and volume signals for MARKSANS — calculated from daily price history

57RSI 14
Neutral — RSI 57

Momentum is balanced — neither overbought nor oversold.

SMA 50
291
▲ Price above SMA 50 — Short-term bullish
SMA 200
218
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
4789K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Marksans Pharma Limited Financial Statements

Annual income statement, balance sheet and cash flow for Marksans Pharma Limited (MARKSANS) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Marksans Pharma Limited

Loading latest quarterly results...

About MARKSANS (Marksans Pharma Limited)

Marksans Pharma Ltd is a globally oriented pharmaceutical company carving a niche for itself through focused research, rigorous manufacturing standards, and strategic marketing ini...tiatives. They operate across multiple continents, reaching patients in the United States, Europe, Australia, and beyond. Their success stems from a dedication to producing reliable and accessible pharmaceutical formulations, addressing a wide spectrum of health needs. Marksans distinguishes itself by cultivating strong relationships with regulatory bodies and consistently adapting to evolving market demands, ensuring its products remain both compliant and relevant. Through continuous innovation and a commitment to quality, they strive to improve healthcare outcomes on a global scale, solidifying their position as a trusted provider of pharmaceutical solutions. Marksans’ diverse portfolio reflects its commitment to addressing prevalent health challenges worldwide. Their product offerings span a comprehensive range of therapeutic areas, including treatments for pain management, cardiovascular health, neurological disorders, and metabolic conditions. They also provide essential medications for gastrointestinal issues, respiratory ailments, and dermatological conditions, as well as specialized therapies for oncology, allergies, and viral infections. This broad scope allows Marksans to cater to the varied needs of healthcare professionals and patients, ensuring access to vital medications. Furthermore, their dedication extends to preventative care, with a focus on dietary supplements designed to support overall well-being. Marksans’ success hinges on a vertically integrated approach, encompassing every stage from research and development to manufacturing and distribution. Their state-of-the-art manufacturing facilities adhere to the highest international quality standards, ensuring the safety and efficacy of their products. By maintaining strict control over the entire production process, they can guarantee consistency and reliability. Marksans also invests significantly in research and development, fostering innovation and driving the development of new and improved formulations. This commitment to excellence and continuous improvement positions them as a dynamic and forward-thinking player in the pharmaceutical industry.

Company Details

Symbol:MARKSANS
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Mark B. Saldanha
Non-Independent Executive Chairman & MD
Mr. Jitendra M. Sharma
Group Chief Financial Officer
Mr. Harshavardhan Panigrahi
Company Secretary, Manager of Legal & Compliance Officer

MARKSANS Share Price: Frequently Asked Questions

What is the current share price of Marksans Pharma Limited?

Marksans Pharma Limited (MARKSANS) trades at ₹316.45 on NSE and BSE. Market cap ₹14.34K (Cr). Educational data only.

What is the P/E ratio of Marksans Pharma Limited?

Marksans Pharma Limited has a P/E of 27.73x vs industry average 34.89x.

What is the Bull Run score for Marksans Pharma Limited?

Marksans Pharma Limited has a Bull Run score of 68.7/100 based on 25+ financial parameters.

Does Marksans Pharma Limited pay dividends?

Marksans Pharma Limited has a dividend yield of 0.29%. Past dividends don't guarantee future payments.

What is the ROE of Marksans Pharma Limited?

Marksans Pharma Limited has ROE of 25.56%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Marksans Pharma Limited?

Marksans Pharma Limited has debt-to-equity of 0.01.

Is Marksans Pharma Limited a good investment?

Bull Run gives Marksans Pharma Limited a score of 68.7/100. This is not investment advice — consult a SEBI-registered advisor.